DATE & TIME
Tuesday, June 2, 2015
11:45 am – 1:30 pm
Maggiano's Little Italy
The Streets at SouthPoint
8030 Renaissance Parkway Suite 890
Durham, NC 27713
Corporate Venture Capital in the Life Science Industry
Steven E. Hall, Ph.D., Lilly Ventures
Derek Norman, Syngenta Ventures
Steve Hall of Lilly Ventures and Derek Norman of Syngenta Ventures will be on hand to participate in a panel discussion covering, among other things, the investment environment in their respective industries and the uniqueness of venture capital funded by their corporate stakeholder. Attendee participation is welcomed.
11:45 AM – 12:00 PM Registration, Networking and Appetizers
12:00 PM – 1:30 PM Lunch and Speaker
Early by May 20, 2015
LES Members: $35
Regular & Onsite
LES Members: $40
Please note that space is limited, so please register early and note that onsite registration will be subject to available seating.
Online Registration Deadline: May 28, 2015, 12 PM EDT
No refunds after Monday, May 20, 2015
Substitutions are permitted
Steve Hall is currently a General Partner at Lilly Ventures, following more than 25 years of drug discovery experience at both multinational pharmaceutical companies and biotech organizations. Prior to joining Lilly Ventures in 2009, Steve was Senior Vice President, Research and Development, at Serenex, Inc. which was acquired by Pfizer in April 2008. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. Steve is an author/co-author of more than 40 papers and 60 patents. He received his B.S. in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology. Steve serves as CEO of Esanex, Inc. and sits on the boards of Cerulean Pharma, Esanex, FORMA Therapeutics, Hydra Biosciences, Lysosomal Therapeutics, Numerate, and Nimbus Therapeutics.
Derek Norman is a Managing Director of Syngenta Ventures, the corporate venture capital group of Syngenta. Syngenta, with a product portfolio in crop protection and seeds, is one of the world’s largest companies focused on increasing agricultural productivity. Derek joined Syngenta Ventures as one of the founding members, where he manages investments across the agricultural value chain, including Agrimetis LLC, Biognosys AG, Illumitex Inc., and Marrone Bio Innovations, Inc. Prior to Syngenta, he was with Hatteras Venture Partners. Derek holds a B.S. degree in chemistry, with Honors, from Stanford University, a Ph.D. degree in Chemistry and Chemical Biology from Harvard University, and he is a member of Phi Beta Kappa.